Sudarshan Pharma Industries Ltd. Fundamental Analysis (BSE: SUDARSHAN.BO)
Sudarshan Pharma Industries Ltd. Fundamental Analysis (BSE: SUDARSHAN.BO)
Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) shows weak financial fundamentals with a PE ratio of 29.48, profit margin of 3.43%, and ROE of 16.97%. The company generates $7.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SUDARSHAN.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakSUDARSHAN.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateSUDARSHAN.BO shows balanced valuation metrics.
Growth Score
ModerateSUDARSHAN.BO shows steady but slowing expansion.
Financial Health Score
ModerateSUDARSHAN.BO shows balanced financial health with some risks.
Profitability Score
WeakSUDARSHAN.BO struggles to sustain strong margins.
Key Financial Metrics
Is SUDARSHAN.BO Expensive or Cheap?
P/E Ratio
SUDARSHAN.BO trades at 29.48 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, SUDARSHAN.BO's PEG of -0.41 indicates potential undervaluation.
Price to Book
The market values Sudarshan Pharma Industries Ltd. at 4.99 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 12.25 times EBITDA. This signals the market has high growth expectations.
How Well Does SUDARSHAN.BO Make Money?
Net Profit Margin
For every $100 in sales, Sudarshan Pharma Industries Ltd. keeps $3.43 as profit after all expenses.
Operating Margin
Core operations generate 7.08 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $16.97 in profit for every $100 of shareholder equity.
ROA
Sudarshan Pharma Industries Ltd. generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sudarshan Pharma Industries Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Sudarshan Pharma Industries Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
SUDARSHAN.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.41
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.99
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.07
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.17
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How SUDARSHAN.BO Stacks Against Its Sector Peers
| Metric | SUDARSHAN.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.48 | 31.29 | Neutral |
| ROE | 16.97% | 543.00% | Weak |
| Net Margin | 3.43% | 8965.00% | Weak |
| Debt/Equity | 0.00 | 0.51 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 5.79 | Weak Liquidity |
| ROA | 0.00% | -96.00% (disorted) | Weak |
SUDARSHAN.BO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sudarshan Pharma Industries Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation